gq1001
mAbexperimentalADC
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 7, 2020 (NCT04450732)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
ERBB2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- maytansinoid
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05575804 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2022 | Fudan University, GeneQuantum Healthcare (Suzhou) Co., Ltd. |
| NCT04450732 | Phase 1 | Jul 7, 2020 | CRC Malaysia, GeneQuantum Healthcare (Suzhou) Co., Ltd., University of Texas at Houston |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GeneQuantum Healthcare (Suzhou) Co., Ltd. | For profit | 2 | 1 | 2 | 2020 |
| CRC Malaysia | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2020 |
4 organizations
Page 1 / 1